

Refine Search

Search Results -

Terms	Documents
L11 same L3	32

Database:

US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Search:

L12

Refine Search

Recall Text

Clear

Interrupt

Search History

DATE: Monday, March 01, 2004 [Printable Copy](#) [Create Case](#)

Set Name Query

side by side

Hit Count Set Name

result set

DB=USPT; PLUR=YES; OP=ADJ

<u>L12</u>	L11 same l3	32	<u>L12</u>
<u>L11</u>	il-6 same (l1 or l5) same 17	95	<u>L11</u>
<u>L10</u>	L9 and l8	48	<u>L10</u>
<u>L9</u>	il-6	4419	<u>L9</u>
<u>L8</u>	L7 and l6	69	<u>L8</u>
<u>L7</u>	bone	66866	<u>L7</u>
<u>L6</u>	L5 same l3	102	<u>L6</u>
<u>L5</u>	anti-cytokine	207	<u>L5</u>
<u>L4</u>	L3 same l2 same l1	2074	<u>L4</u>
<u>L3</u>	in vivo or therapy or inhibit\$	422134	<u>L3</u>
<u>L2</u>	cytokine or cytokines	17324	<u>L2</u>
<u>L1</u>	antibody or antibodies	67564	<u>L1</u>

END OF SEARCH HISTORY

4994 S IL-11 OR INTERLEUKIN-11
L2 673 S L1 (P) ANTIBOD?
L3 404 S L2 (P) (ADMINIST? OR THERAP? OR TREAT? OR METHOD?)

=> s l1 (5a) antibod?
L4 89 L1 (5A) ANTIBOD?

=> s l4 (5a) (administ? or therap? or treat? or method?)
L5 9 L4 (5A) (ADMINIST? OR THERAP? OR TREAT? OR METHOD?)

=> d l5 1-9 bib kwic

L5 ANSWER 1 OF 9 MEDLINE on STN
AN 2002322722 MEDLINE
DN PubMed ID: 12065535
TI Contribution of interleukin-11 and prostaglandin(s) in
lipopolysaccharide-induced bone resorption in vivo.
AU Li Li; Khansari Alireza; Shapira Lior; Graves Dana T; Amar Salomon
CS Department of Periodontology and Oral Biology, School of Dental Medicine,
Boston University, Boston, Massachusetts 02118, USA.
NC 12482 (NIDCR)
DE07559
SO Infection and immunity, (2002 Jul) 70 (7) 3915-22.
Journal code: 0246127. ISSN: 0019-9567.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200207
ED Entered STN: 20020615
Last Updated on STN: 20020731
Entered Medline: 20020730
AB . . . lacking IL-1 receptor type I (IL-1RI(-/-)), mice lacking TNF
receptor p55 and IL-1RI (TNFRp55(-/-)-IL-1RI(-/-)), and wild-type mice.
Mice were then **treated** with injections of anti-IL-
11 monoclonal **antibody** (MAb), indomethacin, or
phosphate-buffered saline (PBS) and sacrificed 5 days later. Histological
sections stained for tartrate-resistant acid phosphatase (TRAP) were. .

L5 ANSWER 2 OF 9 MEDLINE on STN
AN 1999069250 MEDLINE
DN 99069250 PubMed ID: 9767454
TI An anti-inflammatory role for interleukin-11 in established murine
collagen-induced arthritis.
AU Walmsley M; Butler D M; Marinova-Mutafchieva L; Feldmann M
CS Kennedy Institute of Rheumatology, London, UK.
SO IMMUNOLOGY, (1998 Sep) 95 (1) 31-7.
Journal code: 0374672. ISSN: 0019-2805.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199901
ED Entered STN: 19990209
Last Updated on STN: 19990209
Entered Medline: 19990128
AB . . . of IL-11 that the anticollagen type II (CII) response may have
been augmented, there was no statistically significant effect of
IL-11 treatment on anti-CII **antibody**
levels. Similarly, the acute-phase reactant serum amyloid P was only
elevated in mice receiving very high doses (50-100 microgram/day) of. .

L5 ANSWER 3 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:965157 CAPLUS
 DN 138:38076
 TI WSX receptor agonist antibodies for treating diseases associated with lymphopoiesis, erythropoiesis, myelopoiesis, and obesity
 IN Carter, Paul J.; Chiang, Nancy Y.; Kim, Kyung Jin; Matthews, William; Rodrigues, Maria L.
 PA USA
 SO U.S. Pat. Appl. Publ., 140 pp., Cont.-in-part of U.S. Ser. No. 667,197.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 2002193571	A1	20021219	US 1997-779457	19970107
	CA 2241564	AA	19970717	CA 1997-2241564	19970107
	ZA 9700148	A	19980708	ZA 1997-148	19970108
	US 6541604	B1	20030401	US 1997-780562	19970108
	US 2003004109	A1	20030102	US 2002-214802	20020806
PRAI	US 1996-585005	B2	19960108		
	US 1996-667197	A2	19960620		
	US 1996-64855P	P	19960108		
	US 1997-780562	A3	19970108		

IT Cytokines
 Interleukin 1
 Interleukin 10
Interleukin 11
 Interleukin 2
 Interleukin 3
 Interleukin 4
 Interleukin 5
 Interleukin 6
 Interleukin 7
 Interleukin 8
 Interleukin 9

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (WSX receptor **antibodies** for **treating** diseases
 associated with lymphopoiesis, erythropoiesis, myelopoiesis, and obesity)

L5 ANSWER 4 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2002:489736 CAPLUS
 DN 137:183745
 TI Contribution of interleukin-11 and prostaglandin(s) in lipopolysaccharide-induced bone resorption in vivo
 AU Li, Li; Khansari, Alireza; Shapira, Lior; Graves, Dana T.; Amar, Salomon
 CS Department of Periodontology and Oral Biology, School of Dental Medicine, Boston University, Boston, MA, 02118, USA
 SO Infection and Immunity (2002), 70(7), 3915-3922
 CODEN: INFIBR; ISSN: 0019-9567
 PB American Society for Microbiology
 DT Journal
 LA English

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB We previously demonstrated that interleukin-1 (IL-1) and tumor necrosis factor (TNF) activities only partially account for calvarial bone resorption induced by local application of lipopolysaccharide (LPS) in mice. The present study was undertaken to determine the role and relative contribution of IL-11 and prostaglandin(s) (PG[s]) in LPS-induced bone resorption in vivo. A one-time dose of LPS was injected into the s.c. tissue overlying calvaria of mice lacking IL-1 receptor type I (IL-1RI-/-), mice lacking TNF receptor p55 and IL-1RI (TNFRp55-/-IL-1RI-/-), and wild-type mice. Mice were then **treated** with injections

of anti-IL-11 monoclonal antibody (MAB), indomethacin, or phosphate-buffered saline (PBS) and sacrificed 5 days later. Histol. sections stained for tartrate-resistant acid phosphatase (TRAP) were quantified by histomorphometric anal. At low doses of LPS (100 µg/mouse), the percentages of bone surface covered by osteoclasts were found to be similar in three strains of mice. The increase was reduced by 37% with anti-IL-11 MAB and by 46% with indomethacin. At higher doses of LPS (500 µg/mouse), we found an eightfold increase in these percentages in wild-type mice and a fivefold increase in these percentages in IL-1RI-/- and TNFRp55-/-IL-1RI-/- mice after normalizing with the value from the saline-PBS control group in the same strain of mice. The increase was reduced by 55 and 69% in wild-type mice and by 50 and 57% in IL-1RI-/- and TNFRp55-/-IL-1RI-/- mice treated with anti-IL-11 MAB or indomethacin, resp. Our findings suggest that in vivo, at low doses of LPS (100 µg/mouse), LPS-induced bone resorption is mediated by IL-11 and PGs, while at high doses of LPS (500 µg/mouse), it is mediated by IL-11, PGs, IL-1, and TNF signaling. IL-11 and PGs mediate LPS-induced bone resorption by enhancing osteoclastogenesis independently of the IL-1 or TNF signaling.

L5 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:101180 CAPLUS
 DN 134:161896
 TI Mammalian cytokines; related reagents
 IN Timans, Jacqueline C.; Kastelein, Robert A.; Bazan, J. Fernando
 PA Schering Corporation, USA
 SO PCT Int. Appl., 73 pp.
 CODEN: PIXXD2

DT Patent
 LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001009176	A2	20010208	WO 2000-US20475	20000727
	WO 2001009176	A3	20011101		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	EP 1200592	A2	20020502	EP 2000-950787	20000727
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
	JP 2003506026	T2	20030218	JP 2001-513982	20000727
PRAI	US 1999-364674	A	19990730		
	US 1999-369643	A	19990806		
	WO 2000-US20475	W	20000727		

IT **Antibodies**

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (mammalian interleukin 80D and **interleukin 11** for diagnosis and **therapy** of degenerative or abnormal condition of immune system and/or hematopoietic cells)

IT **Antibodies**

RL: BSU (Biological study, unclassified); BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (monoclonal; mammalian interleukin 80D and **interleukin 11** for diagnosis and **therapy** of degenerative or abnormal condition of immune system and/or hematopoietic cells)

L5 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1999:753092 CAPLUS
 DN 132:2795
 TI Antagonists of interleukin 11-mediated osteoporotic bone loss
 IN Shaughnessy, Stephen; Austin, Richard Carl
 PA Hamilton Civic Hospital Research Development Corporation, Can.
 SO PCT Int. Appl., 61 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9959608	A2	19991125	WO 1999-CA516	19990519
	WO 9959608	A3	20000406		
	W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	CA 2328486	AA	19991125	CA 1999-2328486	19990519
	AU 9940277	A1	19991206	AU 1999-40277	19990519
	AU 767749	B2	20031120		
	EP 1079847	A2	20010307	EP 1999-923352	19990519
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	JP 2002515444	T2	20020528	JP 2000-549272	19990519
PRAI	CA 1998-2237915	A	19980519		
	WO 1999-CA516	W	19990519		

IT **Antibodies**
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (neutralizing; to interleukin-11 or IL-11 receptor
 for osteoporosis **therapy**)

L5 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1998:586896 CAPLUS
 DN 129:301592
 TI An anti-inflammatory role for interleukin-11 in established murine collagen-induced arthritis
 AU Walmsley, M.; Butler, D. M.; Marinova-Mutafchieva, L.; Feldmann, M.
 CS Kennedy Inst. of Rheumatology, London, UK
 SO Immunology (1998), 95(1), 31-37
 CODEN: IMMUAM; ISSN: 0019-2805
 PB Blackwell Science Ltd.
 DT Journal
 LA English

RE.CNT 31 THERE ARE 31 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

AB Interleukin-11 (IL-11) is a cytokine belonging to the IL-6 family which has both pro- and anti-inflammatory potential. Like IL-6 it can diminish tumor necrosis factor- α and IL-1 production, and augment Ig synthesis. We have explored the immunomodulatory effects of IL-11 treatment in mice in a model of inflammatory autoimmune joint disease, collagen-induced arthritis (CIA). Recombinant human IL-11 was administered at various doses to DBA/1 mice after the onset of CIA. IL-11 treatment caused a significant reduction in the clin. severity established CIA, which was associated with protection from joint damage, as assessed by histol. Although there was a suggestion at high doses of IL-11 that the anticollagen type II (CII) response may have been augmented, there was no statistically significant effect of IL-11 treatment on

anti-CII **antibody** levels. Similarly, the acute-phase reactant serum amyloid P was only elevated in mice receiving very high doses (50-100 µg/day) of IL-11. Endogenous IL-11 was abundantly produced in synovial membrane cultures derived from CII-immunized mice with active disease, suggesting that, as in rheumatoid arthritis, this cytokine is spontaneously produced in the inflammatory response in CIA. The results presented here demonstrate an anti-arthritis immunoregulatory role for IL-11 in murine CIA, and suggest that IL-11 is a candidate therapeutic mol. for human inflammatory arthritic diseases.

L5 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2004 ACS on STN

AN 1996:681971 CAPLUS

DN 126:6450

TI Anti-gp130 monoclonal antibodies for inflammatory disease treatment

IN Burstein, Samuel A.

PA The Board of Regents of the University of Oklahoma, USA

SO U.S., 14 pp.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5571513	A	19961105	US 1995-455799	19950531
	WO 9638481	A1	19961205	WO 1996-US7385	19960522
	W: AU, CA, JP				
	RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9658695	A1	19961218	AU 1996-58695	19960522
PRAI	US 1995-455799		19950531		
	WO 1996-US7385		19960522		

IT **Interleukin 11**

Interleukin 6

RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)

(anti-gp130 monoclonal **antibodies** for inflammatory disease treatment)

L5 ANSWER 9 OF 9 USPATFULL on STN

AN 2002:19059 USPATFULL

TI Agonist antibodies

IN Adams, Camellia W., Mountain View, CA, United States

Carter, Paul J., San Francisco, CA, United States

Fendly, Brian M., Half Moon Bay, CA, United States

Gurney, Austin L., Belmont, CA, United States

PA Genentech, Inc., South San Francisco, CA, United States (U.S. corporation)

PI US 6342220 B1 20020129

AI US 1997-918148 19970825 (8)

DT Utility

FS GRANTED

EXNAM Primary Examiner: Nolan, Patrick J.

LREP Piper Marbury Rudnick & Wolfe LLP, Kelber, Steven B.

CLMN Number of Claims: 14

ECL Exemplary Claim: 1

DRWN 11 Drawing Figure(s); 11 Drawing Page(s)

LN.CNT 4209

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

DETD . . . stimulating factors or interleukins include; kit-ligand, LIF, G-CSF, GM-CSF, M-CSF, EPO, IL-1, IL-2, IL-3, IL-5, IL-6, IL-7, IL-8, IL-9 or **IL-11**. Alternatively, the **antibody** is **administered** in combination with an Insulin-like growth factor (e.g., IGF-1) or a tumor necrosis factor (e.g., lymphotoxin (LT)).